Table 13.

Indications of individual drug classes based on guidelines and clinical studies [6]

Compelling indication*	Recommended drugs^						Clinical trials basis#
	Diuretic	BB	ACEI	ARB	CCB	ALDO ANT
Heart failure	■	■	■	■		■	ACC/AHA Heart failure Guidelines, MERIT-HF, COPERNICUS, CIBIS, SOLVD, AIRE, TRACE, ValHEFT, RALES
Postmyocardial infraction		■	■	■2	■1	■	ACC/AHA Post-MI Guideline, BHAT, SAVE, Capricorn, EPHESUS
High coronary disease risk	■	■	■		■		ALLHAT, HOPE, ANBP2, LIFE, CONVINCE
Diabetes	■	■	■	■	■		NKF-ADA, Guideline, UKPDS, ALLHAT
Chronic kidney disease			■	■	■3		KDIGO 2021, NKF Guideline, Captopril Trial, RENAAL, IDNT, REIN, AASK
Recurrent stroke prevention	■		■		■4		PROGRESS

¹Option for patients without heart failure or impaired LV function in patients with contraindications to beta-blockers (Danish Verapamil Infarction Trial II–DAVIT)[153]

²If ACEi not tolerated

³First-line antihypertensive agent in adult kidney transplant recipients

⁴A meta-analysis of 13 studies with 1789 subjects randomized to CCBs

^*Compelling indications for antihypertensive drugs are based on benefits from outcome studies or existing clinical guidelines; the compelling indication is managed in parallel with the BP

^{^}Drug abbreviations: ACEI angiotensin-converting enzyme inhibitor, BB beta-blockers, ARB angiotensin receptor blocker, Aldo ANT aldosterone antagonist, CCB calcium channel blocker

^#Conditions for which clinical trials demonstrate the benefit of specific classes of antihypertensive drugs